rss
Evid Based Nurs 7:87 doi:10.1136/ebn.7.3.87
  • Treatment

Review: long acting β2 agonists and inhaled corticosteroids reduce exacerbations in chronic obstructive pulmonary disease

Summary of efficacy data for interventions for chronic obstructive pulmonary disease*

Comparisons RRR/RRI (95% CI)
Exacerbation Mortality
*LAβ2A  =  long acting β2 agonist; SAβ2A  =  short acting β2 agonist; NA  =  not assessed. Other abbreviations defined in glossary; RRR, RRI, and CI calculated from data in article.
†Not significant.
LAβ2A v placebo RRR 21% (10 to 31) RRR 24% (−48 to 61)†
Tiotropium v placebo RRR 26% (11 to 38) NA
Tiotropium v LAβ2A RRR 7% (−8 to 20)† NA
Tiotropium v ipratropium RRR 22% (5 to 37) NA
SAβ2A + anticholinergic v SAβ2A RRR 32% (9 to 49) RRI 18% (−66 to 308)†
SAβ2A + anticholinergic v ipratropium RRI 4% (−35 to 68)† RRI 256% (−41 to 2053)†
Inhaled corticosteroids v placebo RRR 24% (20 to 28) RRR 22% (−5 to 42)†
Inhaled corticosteroids + LAβ2A v placebo RRR 30% (22 to 38) RRR 48% (−34 to 80)†
Inhaled corticosteroids + LAβ2A v LAβ2A RRR 20% (10 to 29) NA
Inhaled corticosteroids + LAβ2A v inhaled corticosteroids RRR 10% (−2 to 20)† NA
Pulmonary rehabilitation v usual care, placebo, or education NA RRR 10% (−24 to 35)†
Supplemental O2v usual care (patients with resting PaO2 <60 mm Hg sea level) NA RRR 39% (18 to 54)
Supplemental O2v usual care (patients with resting PaO2 ⩾60 mm Hg sea level) NA RRI 16% (−15 to 58)†
Disease management v usual care NA RRR 37% (−4 to 62)†

This Article

Free Sample

This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of EBN.
View free sample issue >>

EBN Journal Chat

The EBN Journal Chat offers readers the opportunity to participate in discussion about research articles and commentaries from Evidence Based Nursing (EBN).

How to participate >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

Navigate This Article